# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from ...
Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.0...
After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100%Study ...
IceCure Medical Ltd. (NASDAQ:ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destro...
Study Shows High Complete Ablation Rate And Satisfactory Overall Survival In Breast Cancer Patients; Conducted At University Ho...